Literature DB >> 7851277

HIV infection and cocaine use in methadone maintained and untreated intravenous drug users.

B Meandzija1, P G O'Connor, B Fitzgerald, B J Rounsaville, T R Kosten.   

Abstract

In a survey of 424 intravenous drug users (IVDUs) of whom 107 were currently enrolled in a methadone maintenance program (MMP), we assessed risk behaviors for Human Immunodeficiency Virus (HIV) transmission and conducted HIV testing. We found that African Americans were over-represented in the HIV infected group and under-represented in the methadone maintenance treatment group. Furthermore, subjects in current methadone maintenance treatment reported fewer drug injections in the last 30 days, a reduced speedball (a heroin/cocaine mixture) injection frequency and reduced total cocaine and injected cocaine use. HIV infected subjects reported 20% more cocaine use and injected cocaine use than HIV negatives. However, this difference was due to African Americans reporting more cocaine use and at the same time being over-represented in the HIV infected group. Stratified analysis by ethnicity found significant MMP effects for all ethnic groups, but only one significant HIV status effect, and this was limited to African Americans. Cocaine injection frequency in African Americans was significantly higher for the HIV infected versus non-infected subjects. We conclude that i.v. cocaine use is a risk factor associated with HIV infection and that methadone maintenance treatment is associated with reducing this risk factor. Furthermore, African American cocaine users are at great risk for HIV infection, and increased efforts for engagement in treatment are necessary.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7851277     DOI: 10.1016/0376-8716(94)90092-2

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  16 in total

1.  HIV transmission and the cost-effectiveness of methadone maintenance.

Authors:  G S Zaric; P G Barnett; M L Brandeau
Journal:  Am J Public Health       Date:  2000-07       Impact factor: 9.308

2.  Cost effectiveness of disulfiram: treating cocaine use in methadone-maintained patients.

Authors:  Mireia Jofre-Bonet; Jody L Sindelar; Ismene L Petrakis; Charla Nich; Tami Frankforter; Bruce J Rounsaville; Kathleen M Carroll
Journal:  J Subst Abuse Treat       Date:  2004-04

3.  Spatial patterns of arrests, police assault and addiction treatment center locations in Tijuana, Mexico.

Authors:  Dan Werb; Steffanie A Strathdee; Alicia Vera; Jaime Arredondo; Leo Beletsky; Patricia Gonzalez-Zuniga; Tommi Gaines
Journal:  Addiction       Date:  2016-04-28       Impact factor: 6.526

Review 4.  Drugs of abuse, immune modulation, and AIDS.

Authors:  Guy A Cabral
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-28       Impact factor: 4.147

5.  Lifetime ATS use and increased HIV risk among not-in-treatment opiate injectors in Malaysia.

Authors:  Marek C Chawarski; Balasingam Vicknasingam; Mahmud Mazlan; Richard S Schottenfeld
Journal:  Drug Alcohol Depend       Date:  2012-01-21       Impact factor: 4.492

Review 6.  Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system.

Authors:  Michelle A Patriquin; Isabelle E Bauer; Jair C Soares; David P Graham; David A Nielsen
Journal:  Psychiatr Genet       Date:  2015-10       Impact factor: 2.458

Review 7.  Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection.

Authors:  Linda R Gowing; Michael Farrell; Reinhard Bornemann; Lynn E Sullivan; Robert L Ali
Journal:  J Gen Intern Med       Date:  2005-12-07       Impact factor: 5.128

8.  Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City.

Authors:  D M Hartel; E E Schoenbaum
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

Review 9.  Drug abuse treatment as AIDS prevention.

Authors:  D S Metzger; H Navaline; G E Woody
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

10.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.